CA 15-3: a prognostic marker in breast cancer
CA 15-3: a prognostic marker in breast cancer
复制标题
DOI：
10.1177/172460080001500410
复制
发表时间：
2000-10-01
影响因子：
2
通讯作者：
O'Higgins, N
中科院分区：
文献类型：
--
作者：
Duffy, MJ;Shering, S;O'Higgins, N
CA 15-3（也称为MUC1）是乳腺癌中应用最广泛的血清标志物。MUC1是一种大的跨膜糖蛋白，在癌症中经常过表达和异常糖基化。在生理上，MUC1似乎在细胞粘附中起作用，并且在癌症中存在的高水平可能与转移有关。目前CA 15-3的主要用途是临床前发现复发性乳腺癌和监测晚期乳腺癌患者的治疗。在一项对368例患者的前瞻性研究中，我们发现术前CA 15-3水平高（>30.4 U/mL）的患者比低水平的患者预后更差。在多变量分析中，CA 15-3作为预后标志物与肿瘤大小和淋巴结状态无关。此外，在多变量分析中，CA 15-3对预后的影响比肿瘤大小更强，至少与淋巴结状态一样强。因此，ca15 -3可能是乳腺癌中第一个独立的预后血清标志物。
CA 15-3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer. Physiologically, MUC1 appears to play a role in cell adhesion and the high levels present in cancer may be causally involved in metastasis. At present the main uses of CA 15-3 are in preclinically detecting recurrent breast cancer and monitoring the treatment of patients with advanced breast cancer. In a prospective study of 368 patients we show that patients with high preoperative levels of CA 15-3 (>30.4 U/mL) had a worse outcome than patients with low levels of the marker. In multivariate analysis CA 15-3 as a prognostic marker was independent of both tumor size and nodal status. Furthermore, in multivariate analysis the prognostic impact of CA 15-3 was stronger than that of tumor size and at least as strong as nodal status. CA 15-3 may thus be the first independent prognostic serum marker in breast cancer.